Suppr超能文献

结直肠癌肝转移复发风险的综合评估(CERR)评分:建立与验证

Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation.

机构信息

Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

出版信息

Oncologist. 2020 Jul;25(7):e1031-e1041. doi: 10.1634/theoncologist.2019-0797. Epub 2020 Mar 17.

Abstract

BACKGROUND

The calculation of the tumor burden score (TBS) is not perfect because the bilobar spread of colorectal liver metastasis (CRLM) is neglected. The identification of an ideal prognostic scoring system for CRLM remains controversial.

MATERIALS AND METHODS

Patients who underwent curative intent liver resection for CRLM from one medical center were enrolled in cohort 1 (787 patients) and cohort 2 (162 patients). Tumor relapse-free survival (RFS) was the main outcome. A Cox regression model was used to identify independent predictors of prognosis. The time-dependent area under the curve, calibration curve, and C-index were employed to validate the predictive ability of the survival model.

RESULTS

Modified TBS (mTBS) was established by a mathematical equation with parameters including CRLM size, CRLM number, and unilobar or bilobar metastasis. Five preoperative predictors of worse RFS were identified in cohort 1 and incorporated into the Comprehensive Evaluation of Relapse Risk (CERR) score: KRAS/NRAS/BRAF-mutated tumor (1 point); node-positive primary (1 point); extrahepatic disease (1 point); carcinoembryonic antigen level > 200 ng/mL or carbohydrate antigen 19-9 (CA19-9) >200 U/mL (1 point); and mTBS between 5 and 11 (1 point) or 12 and over (2 points). Patients in cohort 1 were stratified by their CERR score into risk groups: the high-risk group (CERR score 4 or more), the medium-risk group (CERR score 2-3), and the low-risk group (CERR score 0-1). Importantly, internal validation in cohort 1 and further validation in cohort 2 both showed the superior discriminatory capacity of the CERR score.

CONCLUSION

mTBS should be promoted. The CERR score is a powerful prognostic tool that can help determine optimal clinical management strategies.

IMPLICATIONS FOR PRACTICE

This work resulted in the successful modification of the tumor burden score and development of a comprehensive and practical prognostic scoring system-the Comprehensive Evaluation of Relapse Risk (CERR) score. The CERR score, with a better prognostic discriminatory ability, outperformed the Fong score. Perhaps more importantly, the CERR score is a powerful prognostic tool because it unified the most consistently reported prognostic factors. Therefore, the CERR score can assist doctors in determining optimal clinical management strategies.

摘要

背景

肿瘤负担评分(TBS)的计算并不完善,因为结直肠癌肝转移(CRLM)的双侧播散被忽略了。目前对于 CRLM,仍缺乏理想的预后评分系统。

材料与方法

本研究纳入了单中心行根治性肝切除术的 CRLM 患者,将其分为队列 1(787 例患者)和队列 2(162 例患者)。主要研究终点为肿瘤无复发生存(RFS)。采用 Cox 回归模型识别独立预后预测因素。采用时间依赖性曲线下面积、校准曲线和 C 指数来验证生存模型的预测能力。

结果

通过一个包含 CRLM 大小、CRLM 数量以及单侧或双侧转移的数学方程建立了改良 TBS(mTBS)。在队列 1 中发现了 5 个预测 RFS 较差的术前预测因素,并纳入了综合复发风险评估(CERR)评分:KRAS/NRAS/BRAF 突变肿瘤(1 分);阳性淋巴结(1 分);肝外疾病(1 分);癌胚抗原水平>200ng/ml 或碳水化合物抗原 19-9(CA19-9)>200U/ml(1 分);mTBS 为 5-11 分(1 分)或 12 分以上(2 分)。队列 1 中的患者根据 CERR 评分分为高危组(CERR 评分 4 分或更高)、中危组(CERR 评分 2-3 分)和低危组(CERR 评分 0-1 分)。重要的是,队列 1 中的内部验证以及队列 2 中的进一步验证均表明 CERR 评分具有更高的区分能力。

结论

mTBS 应得到推广。CERR 评分是一种强大的预后工具,可以帮助确定最佳的临床管理策略。

临床意义

本研究成功改良了肿瘤负担评分并制定了一种全面实用的预后评分系统——综合复发风险评估(CERR)评分。CERR 评分具有更好的预后区分能力,优于 Fong 评分。更重要的是,CERR 评分是一种强大的预后工具,因为它统一了最一致报道的预后因素。因此,CERR 评分可以帮助医生确定最佳的临床管理策略。

相似文献

1
Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation.
Oncologist. 2020 Jul;25(7):e1031-e1041. doi: 10.1634/theoncologist.2019-0797. Epub 2020 Mar 17.
2
[Long-term outcomes of patients undergoing hepatectomy for bilateral multiple colorectal liver metastases-a propensity score matching analysis].
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Oct 25;23(10):976-983. doi: 10.3760/cma.j.cn.441530-20200414-00204.
3
Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases.
Br J Surg. 2018 Aug;105(9):1210-1220. doi: 10.1002/bjs.10838. Epub 2018 Apr 25.
6
A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy.
Cancer Med. 2021 Mar;10(5):1535-1544. doi: 10.1002/cam4.3697. Epub 2021 Feb 4.
9
Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy.
Int J Colorectal Dis. 2021 Apr;36(4):767-778. doi: 10.1007/s00384-020-03828-z. Epub 2021 Jan 9.

引用本文的文献

1
Outcome prediction after resection of colorectal cancer liver metastases: out with the old, in with the new?
Hepatobiliary Surg Nutr. 2024 Aug 1;13(4):732-735. doi: 10.21037/hbsn-24-187. Epub 2024 Jul 23.
3
Current landscape of preoperative neoadjuvant therapies for initial resectable colorectal cancer liver metastasis.
World J Gastroenterol. 2024 Feb 21;30(7):663-672. doi: 10.3748/wjg.v30.i7.663.
4
The Convergence of Radiology and Genomics: Advancing Breast Cancer Diagnosis with Radiogenomics.
Cancers (Basel). 2024 Mar 6;16(5):1076. doi: 10.3390/cancers16051076.
5
Multimodal Management of Colorectal Liver Metastases: State of the Art.
Oncol Rev. 2024 Jan 4;17:11799. doi: 10.3389/or.2023.11799. eCollection 2023.
8
Predicting early extrahepatic recurrence after local treatment of colorectal liver metastases.
Br J Surg. 2023 Feb 15;110(3):362-371. doi: 10.1093/bjs/znac461.
10
Resection of Colorectal Liver Metastases: Prognostic Impact of Tumor Burden Score Varies with Unilateral Versus Bilateral Metastatic Spread.
J Gastrointest Surg. 2023 Feb;27(2):404-406. doi: 10.1007/s11605-022-05431-9. Epub 2022 Aug 1.

本文引用的文献

1
Survival after repeat hepatectomy for recurrent colorectal liver metastasis: A review and meta-analysis of prognostic factors.
Hepatobiliary Pancreat Dis Int. 2019 Aug;18(4):313-320. doi: 10.1016/j.hbpd.2019.02.003. Epub 2019 Feb 22.
2
The impact of posthepatectomy liver failure on long-term survival after hepatectomy for colorectal liver metastasis.
HPB (Oxford). 2019 Sep;21(9):1185-1193. doi: 10.1016/j.hpb.2019.01.008. Epub 2019 Feb 16.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases.
Br J Surg. 2018 Aug;105(9):1210-1220. doi: 10.1002/bjs.10838. Epub 2018 Apr 25.
6
Biomarkers in colorectal liver metastases.
Br J Surg. 2018 May;105(6):618-627. doi: 10.1002/bjs.10834. Epub 2018 Mar 26.
7
Potential of a cure in patients with colorectal liver metastases and concomitant extrahepatic disease.
J Surg Oncol. 2017 Mar;115(4):488-496. doi: 10.1002/jso.24539. Epub 2017 Mar 31.
10
The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery.
Int J Clin Oncol. 2017 Feb;22(1):96-101. doi: 10.1007/s10147-016-1027-4. Epub 2016 Aug 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验